TriSalus Life Sciences Inc. (NASDAQ: TLSI) has received US Food and Drug Administration 510(k) clearance for TriNav Advance, expanding its Pressure-Enabled Drug Delivery portfolio into procedures requiring access to smaller and more distal blood vessels.
TriNav Advance can be paired with a compatible delivery microcatheter, allowing interventional radiologists to position the company’s SmartValve technology proximal to a treatment site while navigating a separate microcatheter deeper into difficult anatomy. The system can also be used in a high-flow configuration without an additional microcatheter.
TriSalus plans a limited market release over the coming weeks before broader commercialisation. The clearance is financially relevant because delayed FDA timing for TriNav Advance had already contributed to management lowering its 2026 revenue guidance earlier in the year from an initial $60 million-$62 million range to $54 million-$57 million.
Second-quarter revenue reached $11.4 million, and management maintained the $54 million-$57 million full-year target in August. TriNav Advance therefore arrives at a point when TriSalus needs additional product adoption during the second half to support a business that generated $45.2 million of revenue in 2025.
What does TriNav Advance do differently from TriSalus’ existing devices?
TriSalus’ existing TriNav systems use its Pressure-Enabled Drug Delivery approach to change local pressure and flow during infusion, with the goal of increasing therapeutic delivery to target tissue while reducing unintended delivery into surrounding normal structures.
The limitation has been anatomy. Some tumours and embolization targets are supplied through smaller or more tortuous vessels that require a microcatheter to reach the desired treatment location.
TriNav Advance addresses that problem by allowing the SmartValve component to remain more proximal while a compatible microcatheter extends distally. That creates access to cases that the original configuration may not have addressed as easily.
This sounds like a relatively small device modification, but procedural reach can materially influence commercial adoption in interventional radiology. A technology used only in selected anatomies has a smaller practical market than one physicians can incorporate across a broader range of procedures.
Why was FDA timing already affecting TriSalus’ financial guidance?
TriSalus entered 2026 expecting full-year revenue of approximately $60 million to $62 million. It subsequently lowered that range to $54 million-$57 million, citing both first-quarter commercial dynamics and timing of TriNav Advance clearance.
That guidance cut demonstrates why regulatory timing matters even for a 510(k) device rather than a pharmaceutical approval. Sales teams cannot commercially launch a cleared product until the regulatory process is complete, so every month of delay can shift expected product adoption into a later reporting period.
The company generated $8.9 million of first-quarter revenue and $11.4 million in the second quarter. While the sequential improvement was meaningful, TriSalus still needs stronger second-half revenue to reach even the revised annual range.
TriNav Advance can help, but a limited market release means revenue is unlikely to move immediately to full commercial scale. Physician training, hospital purchasing and procedure adoption all need time after clearance.
How large is TriSalus’ existing commercial base?
Full-year 2025 revenue reached approximately $45.2 million, up 53% year over year. That growth established the existing TriNav platform as a real commercial medical-device business rather than an early pre-revenue technology programme.
Second-quarter 2026 revenue of $11.4 million represented continued expansion, and management said broader commercial infrastructure had been put in place to support additional market penetration.
The company also raised $46 million of equity earlier in 2026 and ended the first quarter with $56.6 million of cash, strengthening the balance sheet while funding commercial expansion and its clinical-stage pipeline.
Those investments increase the importance of future revenue growth. A larger sales organisation produces attractive operating leverage only if additional product volume eventually absorbs the cost base built to support it.
Why is liver embolization a meaningful target for PEDD technology?
Liver tumours can be treated through catheter-based procedures in which therapeutic or embolic agents are delivered through arteries feeding the tumour. These approaches can allow physicians to concentrate treatment within the liver while limiting systemic exposure.
Tumour pressure and vascular anatomy can nevertheless make distribution uneven. TriSalus has developed PEDD around the idea that modulating pressure and flow can improve delivery into tumour tissue while reducing unwanted treatment of normal tissue.
The company has generated clinical and real-world evidence around its technology, including a large observational analysis comparing PEDD-treated patients with a much larger non-PEDD group. Such studies can support commercial adoption but do not establish that every individual procedure will produce superior outcomes.
TriNav Advance expands the anatomical reach of that underlying platform, which is why management views the clearance as a portfolio milestone rather than simply another catheter SKU.
Could TriNav Advance take TriSalus beyond liver-directed therapy?
The new device’s regulatory indication supports a broader range of embolization procedures beyond liver therapy, giving TriSalus potential opportunities in areas where physicians need controlled delivery through small vessels.
Management has previously discussed applications including uterine, genicular and thyroid artery embolization as part of the broader addressable market around PEDD technology.
Commercial expansion into those categories will still require physician adoption, clinical evidence and reimbursement economics appropriate to each procedure. A regulatory indication alone does not guarantee hospitals will change established techniques.
The strategic attraction is platform reuse. If one underlying delivery technology can support several procedure categories, TriSalus can potentially expand revenue without creating a completely independent engineering platform for every market.
What should investors watch during the limited market release?
The first measure is physician usage. TriSalus needs evidence that interventional radiologists encounter enough distal or difficult anatomies to make TriNav Advance materially additive to the existing product family.
Revenue mix will provide the second signal. If the device meaningfully contributes during the fourth quarter, the clearance could help TriSalus move toward its $54 million-$57 million 2026 target after the earlier regulatory delay.
The third indicator is broader embolization adoption. Use beyond liver-directed cancer therapy would strengthen the argument that PEDD can become a multi-procedure technology rather than remain concentrated around one clinical niche.
FDA clearance has resolved the regulatory bottleneck that affected TriSalus’ 2026 expectations. The commercial question now becomes measurable: does greater anatomical flexibility create enough incremental procedures to accelerate a medical-device business already generating more than $10 million of quarterly revenue?
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
